阴道分离株的药敏试验。
Determining Susceptibility in Vaginal Isolates.
机构信息
Department of Internal Medicine, Wayne State Universitygrid.254444.7, Detroit, Michigan, USA.
Department of Biochemistry, Microbiology, and Immunology, Wayne State Universitygrid.254444.7, Detroit, Michigan, USA.
出版信息
Antimicrob Agents Chemother. 2022 Jun 21;66(6):e0236621. doi: 10.1128/aac.02366-21. Epub 2022 May 23.
Abstract
Antifungal drug susceptibility tests (AST) for Candida albicans are increasingly demanded for women with refractory or recurrent vaginitis due to fluconazole resistance. Given reduced activity of azole drugs at pH levels found in women with vaginitis, it is proposed that AST be performed at pH 4.5, since testing at only the recommended pH 7.0 is likely to miss a significant number of clinically relevant azole-resistant C. albicans vaginal isolates.
摘要
由于氟康唑耐药，越来越多患有难治性或复发性阴道炎的女性需要进行白色念珠菌的抗真菌药敏试验（AST）。鉴于唑类药物在阴道炎女性中发现的 pH 值水平下活性降低，建议在 pH 4.5 下进行 AST，因为仅在推荐的 pH 7.0 下进行测试可能会错过大量临床上相关的唑类耐药白色念珠菌阴道分离株。
相似文献
1
Determining Susceptibility in Vaginal Isolates.
Antimicrob Agents Chemother. 2022 Jun 21;66(6):e0236621. doi: 10.1128/aac.02366-21. Epub 2022 May 23.
2
Effect of pH on in vitro susceptibility of Candida glabrata and Candida albicans to 11 antifungal agents and implications for clinical use.
Antimicrob Agents Chemother. 2012 Mar;56(3):1403-6. doi: 10.1128/AAC.05025-11. Epub 2012 Jan 9.
3
Reduced fluconazole susceptibility of Candida albicans isolates in women with recurrent vulvovaginal candidiasis: effects of long-term fluconazole therapy.
Diagn Microbiol Infect Dis. 2009 Jul;64(3):354-6. doi: 10.1016/j.diagmicrobio.2009.03.021.
4
A longitudinal study on fluconazole resistance in Candida albicans vaginal isolates.
Mycoses. 2023 Jul;66(7):563-565. doi: 10.1111/myc.13582. Epub 2023 Mar 13.
5
Anidulafungin treatment for fluconazole-resistant vaginitis with cross-resistance to azoles: a case report.
J Obstet Gynaecol. 2021 May;41(4):665-666. doi: 10.1080/01443615.2020.1732893. Epub 2020 Apr 21.
6
A comparative investigation of azole susceptibility in Candida isolates from vulvovaginal candidiasis and recurrent vulvovaginal candidiasis patients in Ghana.
Med Mycol. 2017 Aug 1;55(6):686-689. doi: 10.1093/mmy/myw122.
7
Current treatment options for vulvovaginal candidiasis caused by azole-resistant Candida species.
Expert Opin Pharmacother. 2018 Jun;19(9):971-977. doi: 10.1080/14656566.2018.1476490. Epub 2018 Jun 22.
8
Vulvovaginal candidiasis: species distribution of Candida and their antifungal susceptibility pattern.
BMC Womens Health. 2018 Jun 15;18(1):94. doi: 10.1186/s12905-018-0607-z.
9
[INVESTIGATION ON ANTIFUNGAL SUSCEPTIBILITY OF CANDIDA YEASTS IN PREGNANT PATIENTS WITH CONFIRMED VULVOVAGINAL CANDIDIASIS AND THEIR NEWBORNS.].
Akush Ginekol (Sofiia). 2016;55(4):20-29.
10
Cross-Resistance of clinical isolates of Candida albicans and Candida glabrata to over-the-counter azoles used in the treatment of vaginitis.
Microb Drug Resist. 2000 Summer;6(2):155-61. doi: 10.1089/107662900419474.
引用本文的文献
1
Genetic diversity and antifungal resistance in Candida albicans from VVC cases in Indian women.
BMC Microbiol. 2025 Aug 23;25(1):535. doi: 10.1186/s12866-025-04256-1.
2
Antifungal Testing of Vaginal Isolates in Pregnant Women: A Retrospective, Single-Center Study in Adana, Türkiye.
J Fungi (Basel). 2025 Jan 24;11(2):92. doi: 10.3390/jof11020092.
3
Antifungal susceptibility testing and determination of local epidemiological cut-off values for species isolated from women with vulvovaginal candidiasis.
Microbiol Spectr. 2025 Mar 4;13(3):e0248824. doi: 10.1128/spectrum.02488-24. Epub 2025 Jan 23.
4
Integrating Clinical and Microbiological Expertise to Improve Vaginal Candidiasis Management.
Mycopathologia. 2024 Nov 8;189(6):96. doi: 10.1007/s11046-024-00904-8.
5
Molecular Identification of Fungal Species through Multiplex-qPCR to Determine Candidal Vulvovaginitis and Antifungal Susceptibility.
J Fungi (Basel). 2023 Nov 27;9(12):1145. doi: 10.3390/jof9121145.
6
Resistance to Fluconazole of Candida albicans in Vaginal Isolates: a 10-Year Study in a Clinical Referral Center.
Antimicrob Agents Chemother. 2023 May 17;67(5):e0018123. doi: 10.1128/aac.00181-23. Epub 2023 Apr 24.
本文引用的文献
1
Antifungal Susceptibility Testing: A Primer for Clinicians.
Open Forum Infect Dis. 2021 Sep 9;8(11):ofab444. doi: 10.1093/ofid/ofab444. eCollection 2021 Nov.
2
Analysis of Biofilm-Related Genes and Antifungal Susceptibility Pattern of Vaginal and Non- Species.
Biomed Res Int. 2021 May 28;2021:5598907. doi: 10.1155/2021/5598907. eCollection 2021.
3
Chronic recurrent vulvovaginitis is not only due to Candida.
Rev Iberoam Micol. 2021 Jul-Sep;38(3):132-137. doi: 10.1016/j.riam.2021.03.002. Epub 2021 Jun 4.
4
How to interpret MICs of antifungal compounds according to the revised clinical breakpoints v. 10.0 European committee on antimicrobial susceptibility testing (EUCAST).
Clin Microbiol Infect. 2020 Nov;26(11):1464-1472. doi: 10.1016/j.cmi.2020.06.007. Epub 2020 Jun 17.
5
Antifungal Susceptibility Testing: Current Approaches.
Clin Microbiol Rev. 2020 Apr 29;33(3). doi: 10.1128/CMR.00069-19. Print 2020 Jun 17.
6
Prognosis and Long-Term Outcome of Women With Idiopathic Recurrent Vulvovaginal Candidiasis Caused by Candida albicans.
J Low Genit Tract Dis. 2020 Jan;24(1):48-52. doi: 10.1097/LGT.0000000000000496.
7
A study on biofilm production and antifungal drug resistance among Candida species from vulvovaginal and bloodstream infections.
Infect Drug Resist. 2018 Nov 23;11:2443-2448. doi: 10.2147/IDR.S179462. eCollection 2018.
8
Reduced Antifungal Susceptibility of Vulvovaginal Candida Species at Normal Vaginal pH Levels: Clinical Implications.
J Low Genit Tract Dis. 2018 Apr;22(2):152-158. doi: 10.1097/LGT.0000000000000383.
9
Recurrent vulvovaginal candidiasis.
Am J Obstet Gynecol. 2016 Jan;214(1):15-21. doi: 10.1016/j.ajog.2015.06.067. Epub 2015 Jul 9.
10
Fluconazole-resistant Candida albicans vulvovaginitis.
Obstet Gynecol. 2012 Dec;120(6):1407-14. doi: 10.1097/aog.0b013e31827307b2.
Zotero 插件